The Impact Of COVID-19 On Clinical Trials

08 Jun 2020

• By Dustin Phan

Clinical trials for therapeutic areas aside from COVID-19 are experiencing disruptions and delays as social distancing measures and travel restrictions are implemented across the world.

The biopharmaceutical sector faces disruption to clinical trials at all phases as the coronavirus pandemic continues. Also, some industry players are shifting R&D priorities toward finding new vaccines and treatments for COVID-19, potentially at the expense of other indications.

However, the industry is compelled to maintain its momentum in R&D in order to bring safe and effective therapies to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff

07 May 2024

• By Eleanor Malone

Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.

COVID To GLP-1: Catalent Plants Ride With Novo To Next Public Health Crisis

26 Feb 2024

• By Bowman Cox

A complex transformation is underway as client proposes to acquire CDMO facilities that vaccinated the world against the COVID-19 pandemic for pivot to the obesity epidemic.

Outlook 2024: Biopharma Embraces New Markets And New Tech

06 Dec 2023

• By Lucie Ellis-Taitt

New markets, a patent cliff, an M&A rebound and clinical trial catalysts. How will it all play out for the biopharma sector in 2024?

After All The Layoffs, Is Biopharma’s Headcount Still Growing?

05 Sep 2023

• By Andrew McConaghie

While biotech layoffs and big pharma restructuring dominate the news in 2023, the sector’s job market remains buoyant.

Wide Of The Mark: ‘The Worst EU Medtech Predictions Have Not Come True’

19 Jun 2025

• By Ashley Yeo

Jana Grieb, European regulatory and market access legal expert at McDermott Will & Emery, explains why the healthtech and pharma industries are warming to the new EU health commissioner as he faces calls to make the MDR more “user friendly.”

This Belgian Biotech’s Drug Cocktail Could Help Reverse Muscle Aging

18 Jun 2025

• By Jo Shorthouse

While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist